Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenet... Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. 詳細を表示
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs...
Preliminary CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood test, Epi+Gen CHD is now available at...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood test, Epi+Gen CHD is now available at...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-driven precision cardiovascular medicine, today announced the successful completion of its System and Organization Controls (SOC...
Company to recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the Molecular Diagnostic Services (MolDx) program. Cardio Diagnostics Holdings, Inc. (NASDAQ:...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood tests, Epi+Gen CHD and PrecisionCHD...
The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.71115 | 129.61815365 | 0.54865 | 1.77 | 0.485 | 24200777 | 0.92289759 | CS |
4 | 0.9898 | 366.592592593 | 0.27 | 1.77 | 0.2153 | 11005177 | 0.70462592 | CS |
12 | 0.9688 | 332.920962199 | 0.291 | 1.77 | 0.19 | 6310377 | 0.52534679 | CS |
26 | 0.6598 | 109.966666667 | 0.6 | 1.77 | 0.19 | 3064464 | 0.52119818 | CS |
52 | 0.0098 | 0.784 | 1.25 | 3.56 | 0.19 | 2051091 | 0.8948302 | CS |
156 | -2.9902 | -70.3576470588 | 4.25 | 8.4999 | 0.171 | 3084523 | 1.67409897 | CS |
260 | -2.9902 | -70.3576470588 | 4.25 | 8.4999 | 0.171 | 3084523 | 1.67409897 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約